Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Convertible Debt: 2020-2025

Historic Convertible Debt for Collegium Pharmaceutical (COLL) over the last 6 years, with Sep 2025 value amounting to $237.9 million.

  • Collegium Pharmaceutical's Convertible Debt rose 0.44% to $237.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $237.9 million, marking a year-over-year increase of 0.44%. This contributed to the annual value of $237.2 million for FY2024, which is 9.52% down from last year.
  • Latest data reveals that Collegium Pharmaceutical reported Convertible Debt of $237.9 million as of Q3 2025, which was up 0.11% from $237.7 million recorded in Q2 2025.
  • Collegium Pharmaceutical's 5-year Convertible Debt high stood at $262.4 million for Q1 2024, and its period low was $26.4 million during Q1 2022.
  • Moreover, its 3-year median value for Convertible Debt was $237.9 million (2025), whereas its average is $248.4 million.
  • Its Convertible Debt has fluctuated over the past 5 years, first tumbled by 81.08% in 2022, then skyrocketed by 891.35% in 2023.
  • Collegium Pharmaceutical's Convertible Debt (Quarterly) stood at $140.0 million in 2021, then grew by 0.65% to $140.9 million in 2022, then surged by 86.07% to $262.1 million in 2023, then declined by 9.52% to $237.2 million in 2024, then rose by 0.44% to $237.9 million in 2025.
  • Its last three reported values are $237.9 million in Q3 2025, $237.7 million for Q2 2025, and $237.4 million during Q1 2025.